These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30306872)

  • 21.
    Vaghefinezhad N; Farsani SF; Gharaghani S
    Curr Drug Discov Technol; 2021; 18(1):139-157. PubMed ID: 31721705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ligand and structure-based approaches for the identification of SIRT1 activators.
    Vyas VK; Goel A; Ghate M; Patel P
    Chem Biol Interact; 2015 Feb; 228():9-17. PubMed ID: 25595223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An efficient multistep ligand-based virtual screening approach for GPR40 agonists.
    Yao S; Lu T; Zhou Z; Liu H; Yuan H; Ran T; Lu S; Zhang Y; Ke Z; Xu J; Xiong X; Chen Y
    Mol Divers; 2014 Feb; 18(1):183-93. PubMed ID: 24307222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
    Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
    PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
    Mohammad S
    Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors.
    John S; Thangapandian S; Arooj M; Hong JC; Kim KD; Lee KW
    BMC Bioinformatics; 2011 Dec; 12 Suppl 14(Suppl 14):S4. PubMed ID: 22372967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
    Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
    Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3D Pharmacophore-Based Virtual Screening and Docking Approaches toward the Discovery of Novel HPPD Inhibitors.
    Fu Y; Sun YN; Yi KH; Li MQ; Cao HF; Li JZ; Ye F
    Molecules; 2017 Jun; 22(6):. PubMed ID: 28598377
    [No Abstract]   [Full Text] [Related]  

  • 31. Free fatty acid receptors: structural models and elucidation of ligand binding interactions.
    Tikhonova IG; Poerio E
    BMC Struct Biol; 2015 Sep; 15():16. PubMed ID: 26346819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
    Vyas VK; Ghate M; Goel A
    J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation.
    Qiu Y; Zhou L; Hu Y; Bao Y
    J Recept Signal Transduct Res; 2019 Apr; 39(2):154-166. PubMed ID: 31355691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CoMSIA study on substituted aryl alkanoic acid analogs as GPR40 agonists.
    Bhatt A; Patel PD; Patel MR; Singh S; Lau-Cam CA; Talele TT
    Chem Biol Drug Des; 2011 May; 77(5):361-72. PubMed ID: 21352503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of Camptothecin Based Topoisomerase I Inhibitors: Identification Using an Atom Based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach.
    Dev S; Dhaneshwar SR; Mathew B
    Comb Chem High Throughput Screen; 2016; 19(9):752-763. PubMed ID: 27515040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The first pharmacophore model for potent G protein-coupled receptor 119 agonist.
    Zhu X; Huang D; Lan X; Tang C; Zhu Y; Han J; Huang W; Qian H
    Eur J Med Chem; 2011 Jul; 46(7):2901-7. PubMed ID: 21524831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GPR40: a therapeutic target for mediating insulin secretion (review).
    Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL
    Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
    Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
    J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity.
    Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S
    SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GPR40-Mediated G
    Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
    Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.